FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3106783062> ?p ?o ?g. }

• W3106783062 abstract "Abstract An uncontrolled increase in cytokine production may lead to systemic hyperinflammation, vascular hypo-responsiveness, increased endothelial permeability, hypercoagulation, multi-organ dysfunction and eventually death in moderate to severely ill COVID-19 patients. Targeting T-cells, an important driver of the hyperinflammatory response, in the treatment of COVID-19, could potentially reduce mortality and improve survival rates. Itolizumab is an anti-CD6 humanized monoclonal antibody with an immunomodulating action on T effector cells that downregulates T-cell activation, proliferation and subsequent production of various chemokines and cytokines. The efficacy and safety of Itolizumab for the treatment of cytokine release syndrome in patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 was evaluated in a multi-centric, open-label, two-arm, controlled, randomized, phase 2 study. Eligible patients were randomized (2:1) to arm A (best supportive care + Itolizumab) and arm B (best supportive care). The primary outcome of interest was reduction in all-cause mortality 30 days after enrolment. Thirty-six patients were screened, 5 were treated as first dose sentinels and the rest were randomized, whilst 4 patients were considered screen failures. Two patients in the Itolizumab treatment arm discontinued prior to receiving the first dose and were replaced. At the end of 1 month, there were 3 deaths in arm B, and none in arm A (p= 0.0296). At the end of the follow-up period, more patients in Arm A had improved SpO2 without increasing FiO2 (p=0.0296), improved PaO2 (p=0.0296), and reduction in IL-6 (43 pg/ml vs 212 pg/ml; p=0.0296) and tumor necrotic factor-α (9 pg/ml vs 39 pg/ml; p=0.0253) levels. Itolizumab was generally safe and well tolerated, and transient lymphopenia (11 patients in Arm A) and infusion reactions (7 patients) were the commonly reported treatment related safety events. These encouraging results indicate that larger clinical trials are warranted to establish the role of Itolizumab in controlling immune hyperactivation in COVID-19." @default.
• W3106783062 created "2020-12-07" @default.
• W3106783062 creator A5000982656 @default.
• W3106783062 creator A5002787630 @default.
• W3106783062 creator A5021865795 @default.
• W3106783062 creator A5025363045 @default.
• W3106783062 creator A5027767574 @default.
• W3106783062 creator A5033769407 @default.
• W3106783062 creator A5041082309 @default.
• W3106783062 creator A5071740303 @default.
• W3106783062 creator A5073671850 @default.
• W3106783062 creator A5075141813 @default.
• W3106783062 date "2020-12-02" @default.
• W3106783062 modified "2023-09-23" @default.
• W3106783062 title "A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19" @default.
• W3106783062 cites W1489752262 @default.
• W3106783062 cites W1557441502 @default.
• W3106783062 cites W1872411639 @default.
• W3106783062 cites W1977508422 @default.
• W3106783062 cites W1994006997 @default.
• W3106783062 cites W2002251042 @default.
• W3106783062 cites W2014381340 @default.
• W3106783062 cites W2019324344 @default.
• W3106783062 cites W2139138993 @default.
• W3106783062 cites W2281322842 @default.
• W3106783062 cites W2547035750 @default.
• W3106783062 cites W2560688390 @default.
• W3106783062 cites W2731611291 @default.
• W3106783062 cites W2745903002 @default.
• W3106783062 cites W2757349481 @default.
• W3106783062 cites W3007940623 @default.
• W3106783062 cites W3008461878 @default.
• W3106783062 cites W3009859788 @default.
• W3106783062 cites W3011011733 @default.
• W3106783062 cites W3011779988 @default.
• W3106783062 cites W3011976215 @default.
• W3106783062 cites W3012421327 @default.
• W3106783062 cites W3013486442 @default.
• W3106783062 cites W3014050022 @default.
• W3106783062 cites W3014245512 @default.
• W3106783062 cites W3016010853 @default.
• W3106783062 cites W3016127406 @default.
• W3106783062 cites W3018517500 @default.
• W3106783062 cites W3020901026 @default.
• W3106783062 cites W3021328077 @default.
• W3106783062 cites W3024879069 @default.
• W3106783062 cites W3026137701 @default.
• W3106783062 cites W3027630905 @default.
• W3106783062 cites W3028902173 @default.
• W3106783062 cites W3030748363 @default.
• W3106783062 cites W3030871984 @default.
• W3106783062 cites W3032373213 @default.
• W3106783062 cites W3032663566 @default.
• W3106783062 cites W3032677067 @default.
• W3106783062 cites W3034105463 @default.
• W3106783062 cites W3035060467 @default.
• W3106783062 cites W3036155640 @default.
• W3106783062 cites W3036850492 @default.
• W3106783062 cites W3038242174 @default.
• W3106783062 cites W3040519011 @default.
• W3106783062 cites W3041300800 @default.
• W3106783062 cites W3041464116 @default.
• W3106783062 cites W3041967042 @default.
• W3106783062 cites W3043275684 @default.
• W3106783062 cites W3043308024 @default.
• W3106783062 cites W3043449676 @default.
• W3106783062 cites W3044530856 @default.
• W3106783062 cites W3044857285 @default.
• W3106783062 cites W3044884453 @default.
• W3106783062 cites W3045380118 @default.
• W3106783062 cites W3046457613 @default.
• W3106783062 cites W3046556984 @default.
• W3106783062 cites W4214559180 @default.
• W3106783062 cites W4231745004 @default.
• W3106783062 cites W4238078535 @default.
• W3106783062 cites W605729605 @default.
• W3106783062 doi "https://doi.org/10.1101/2020.12.01.20239574" @default.
• W3106783062 hasPublicationYear "2020" @default.
• W3106783062 type Work @default.
• W3106783062 sameAs 3106783062 @default.
• W3106783062 citedByCount "2" @default.
• W3106783062 countsByYear W31067830622021 @default.
• W3106783062 crossrefType "posted-content" @default.
• W3106783062 hasAuthorship W3106783062A5000982656 @default.
• W3106783062 hasAuthorship W3106783062A5002787630 @default.
• W3106783062 hasAuthorship W3106783062A5021865795 @default.
• W3106783062 hasAuthorship W3106783062A5025363045 @default.
• W3106783062 hasAuthorship W3106783062A5027767574 @default.
• W3106783062 hasAuthorship W3106783062A5033769407 @default.
• W3106783062 hasAuthorship W3106783062A5041082309 @default.
• W3106783062 hasAuthorship W3106783062A5071740303 @default.
• W3106783062 hasAuthorship W3106783062A5073671850 @default.
• W3106783062 hasAuthorship W3106783062A5075141813 @default.
• W3106783062 hasBestOaLocation W31067830621 @default.
• W3106783062 hasConcept C126322002 @default.
• W3106783062 hasConcept C13373296 @default.
• W3106783062 hasConcept C141071460 @default.
• W3106783062 hasConcept C168563851 @default.
• W3106783062 hasConcept C2776348555 @default.
• W3106783062 hasConcept C2776914184 @default.

• next